Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib.
about
Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@en
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@nl
type
label
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@en
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@nl
prefLabel
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@en
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@nl
P2093
P2860
P356
P1433
P1476
Three Years Sustained Complete ...... phoma Treated with Crizotinib.
@en
P2093
Carolina Valeria Mahuad
Claudia Casali
Gonzalo Garate
Marta E Zerga
María Florencia Aizpurua
María de Los Ángeles Vicente Repáraz
P2860
P356
10.4081/RT.2016.6266
P577
2016-06-28T00:00:00Z